SCHEMBL26098984

SCHEMBL26098984

COc1ccc(CN(C)c2cc(Nc3cccc(-c4ccc(C5OCCO5)cn4)c3OC)nn3c(C(=O)N[C@@H]4C[C@@H]4F)cnc23)cc1

nearest known ligand 0.41

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ TYK2 P29597 20/20 0.41
▸ PDE4D Q08499 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30392624 1.00 TYK2 (0.41) TYK2PDE4D
SCHEMBL26100209 0.95 TYK2 (0.41) TYK2PDE4D
SCHEMBL30392548 0.95 TYK2 (0.41) TYK2PDE4D
SCHEMBL26099770 0.95 TYK2 (0.40) TYK2PDE4D
SCHEMBL26103008 0.94 TYK2 (0.37) TYK2PDE4D
SCHEMBL30392922 0.94 TYK2 (0.37) TYK2PDE4D
SCHEMBL26097592 0.94 TYK2 (0.39) TYK2PDE4D
SCHEMBL30391990 0.94 TYK2 (0.42) TYK2PDE4D
SCHEMBL26099211 0.94 TYK2 (0.42) TYK2PDE4D
SCHEMBL30392279 0.92 TYK2 (0.37) TYK2PDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250051338-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-02-13 — — US disclosed
WO-2023076161-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-05-04 — — WO disclosed
WO-2023076161-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-05-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250051338-A1 TYK2 DEGRADERS AND USES THEREOF TYK2, DYRK2, DYRK1A TYK2 1/4885PDE4D 4649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback